Skip to main content
SpringerLink
Log in

Soluble transferrin receptor and depth of bone marrow suppression following high dose chemotherapy

  • Short Communication
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

Soluble transferrin receptor (sTfR) reflects erythropoietic activity in the bone marrow. We have sought to identify whether serial measurement of sTfR may predict depth or duration of myelosuppression in patients receiving high dose chemotherapy.

Materials and methods

We prospectively measured serial sTfR in nine consecutive patients with haematologic malignancy admitted for various high dose regimens. The sTfR nadir was associated with white cell nadir, and sTfR nadir and day 5 sTfR were inversely associated with the number of red cell transfusions required.

Conclusion

Our data suggest that sTfR may be helpful in predicting the degree of bone marrow suppression in patients receiving intensive chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Beguin Y (1992) The soluble transferrin receptor: biological aspects and clinical usefulness as quantitative measure of erythropoiesis. Haematologica 77:1–10

    PubMed  CAS  Google Scholar 

  2. Beguin Y (2003) Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 329:9–22. doi:10.1016/S0009-8981(03)00005-6

    Article  PubMed  CAS  Google Scholar 

  3. Corazza F, Beguin Y, Bergmann P, Andre M, Ferster A, Devalck C, Fondu P, Buyse M, Sariban E (1998) Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood 92:1793–1798

    PubMed  CAS  Google Scholar 

  4. Estey E, Döhner H (2006) Acute myeloid leukaemia. Lancet 368:1894–1907. doi:10.1016/S0140-6736(06)69780-8

    Article  PubMed  Google Scholar 

  5. Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA (1990) Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 75:102

    PubMed  CAS  Google Scholar 

  6. Kimby E, Nygren P, Glimelius B (2001) A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncologica 40:231–252

    Article  PubMed  CAS  Google Scholar 

  7. Pfeiffer CM, Cook JD, Mei Z, Cogswell ME, Looker AC, Lacher DA (2007) Evaluation of an automated soluble transferrin receptor (sTfR) assay on the Roche Hitachi analyzer and its comparison to two ELISA assays. Clin Chim Acta 382:112–116

    Article  PubMed  CAS  Google Scholar 

  8. Punnonen K, Irjala K, Rajamaki A (1997) Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 89:1052–1057

    PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

We have no conflicts of interest to declare.

Funding

The study was supported by internal departmental funding.

Author information

Authors and Affiliations

  1. Department of Clinical Haematology and Bone Marrow Transplant, The Alfred Hospital, Commercial Road, Melbourne, 3004, Victoria, Australia

    Sant-Rayn Pasricha

  2. Alfred Pathology Service, The Alfred Hospital, Commercial Road, Melbourne, 3004, Victoria, Australia

    Poyap Rooney & Hans Schneider

Authors
  1. Sant-Rayn Pasricha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Poyap Rooney
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans Schneider.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pasricha, SR., Rooney, P. & Schneider, H. Soluble transferrin receptor and depth of bone marrow suppression following high dose chemotherapy. Support Care Cancer 17, 847–850 (2009). https://doi.org/10.1007/s00520-009-0584-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-009-0584-8

Keywords

Search

Navigation